Abstract
It is now well accepted that receptors can regulate cellular signaling pathways in the absence of a stimulating ligand, and inverse agonists can reduce this ligand-independent or “constitutive” receptor activity. Both the serotonin 5-HT2A and 5-HT2C receptors have demonstrated constitutive receptor activity in vitro and in vivo. Each has been identified as a target for treatment of schizophrenia. Further, most, if not all, atypical antipsychotic drugs have inverse agonist properties at both 5-HT2A and 5-HT2C receptors. This paper describes our current knowledge of inverse agonism of atypical antipsychotics at 5-HT2A/2C receptor subtypes in vitro and in vivo. Exploiting inverse agonist properties of APDs may provide new avenues for drug development.
Keywords: Antipsychotic drugs, atypical antipsychotic drugs, inverse agonism, constitutive activity, serotonin, 5-HT2A receptors, 5-HT2C receptors, schizophrenia.
Current Pharmaceutical Design
Title:Atypical antipsychotics and inverse agonism at 5-HT2 receptors
Volume: 21 Issue: 26
Author(s): Laura C. Sullivan, William P Clarke and Kelly A. Berg
Affiliation:
Keywords: Antipsychotic drugs, atypical antipsychotic drugs, inverse agonism, constitutive activity, serotonin, 5-HT2A receptors, 5-HT2C receptors, schizophrenia.
Abstract: It is now well accepted that receptors can regulate cellular signaling pathways in the absence of a stimulating ligand, and inverse agonists can reduce this ligand-independent or “constitutive” receptor activity. Both the serotonin 5-HT2A and 5-HT2C receptors have demonstrated constitutive receptor activity in vitro and in vivo. Each has been identified as a target for treatment of schizophrenia. Further, most, if not all, atypical antipsychotic drugs have inverse agonist properties at both 5-HT2A and 5-HT2C receptors. This paper describes our current knowledge of inverse agonism of atypical antipsychotics at 5-HT2A/2C receptor subtypes in vitro and in vivo. Exploiting inverse agonist properties of APDs may provide new avenues for drug development.
Export Options
About this article
Cite this article as:
Sullivan C. Laura, Clarke P William and Berg A. Kelly, Atypical antipsychotics and inverse agonism at 5-HT2 receptors, Current Pharmaceutical Design 2015; 21 (26) . https://dx.doi.org/10.2174/1381612821666150605111236
DOI https://dx.doi.org/10.2174/1381612821666150605111236 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface [Hot topic: Protein Crystallography in Drug Design (Guest Editor: Jonathan B. Cooper)]
Current Drug Targets Factors of Rapid Cognitive Decline in Late Onset Alzheimer's Disease
Current Aging Science Treatment of Diabetic Foot Ulcer: An Overview Strategies for Clinical Approach
Current Diabetes Reviews Modulators of Vascular Sex Hormone Receptors and their Effects in Estrogen-Deficiency States Associated with Menopause
Recent Patents on Cardiovascular Drug Discovery Neurological Soft Signs in Patients with Psychosis and Cannabis Abuse: A Systematic Review and Meta-Analysis of Paradox
Current Pharmaceutical Design Bowel Habit in Preterm New borns: Effect of New Formulas
Endocrine, Metabolic & Immune Disorders - Drug Targets Characteristics of Insomniacs Having Sleep State Misperception
Neuroscience and Biomedical Engineering (Discontinued) The Long-Term Effect of Medically Enhancing Melanin Intrinsic Bioenergetics Capacity in Prematurity
Current Genomics Targeting Protein-Protein Interactions in the Proteasome Super-Assemblies.
Current Topics in Medicinal Chemistry The Peripheral Anionic Site of Acetylcholinesterase: Structure, Functions and Potential Role in Rational Drug Design
Current Pharmaceutical Design Consciousness, Functional Networks and Delirium Screening
Current Aging Science Genetics of Opioid Dependence: A Review of the Genetic Contribution to Opioid Dependence
Current Psychiatry Reviews Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Extraction, Characterization and In Vivo Neuromodulatory Activity of Phytosterols from Microalga Dunaliella Tertiolecta
Current Medicinal Chemistry Commentary (Research Highlights Utilizing Neuro-Inflammation: Turning Degeneration to Regeneration)
CNS & Neurological Disorders - Drug Targets A2B Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry From Gene to Epigene-Based Therapies Targeting the Vascular Endothelium
Current Vascular Pharmacology Gabapentin and Pregabalin for the Acute Post-operative Pain Management. A Systematic-narrative Review of the Recent Clinical Evidences
Current Drug Targets The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders
Current Molecular Pharmacology Inhibition of Early Biochemical Defects in Prodromal Huntington’s disease by Simultaneous Activation of Nrf2 and Elevation of Multiple Micronutrients
Current Aging Science